Eqis Capital Management, Inc. Bria Cell Therapeutics Corp. Transaction History

Eqis Capital Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.91 - $10.14 $95,588 - $164,004	-16,174 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.1 - $10.61 $3,372 - $5,039	-475 Reduced 2.85%	16,174 $134,000
Q3 2021 Nov 12, 2021	SELL	$4.4 - $9.28 $19,945 - $42,066	-4,533 Reduced 21.4%	16,649 $135,000
Q2 2021 Aug 12, 2021	BUY	$2.89 - $6.57 $13,996 - $31,818	4,843 Added 29.64%	21,182 $113,000
Q1 2021 May 14, 2021	BUY	$3.15 - $6.17 $51,467 - $100,811	16,339 New	16,339 $63,000

Ticker BCTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,518,000
Market Cap $16M
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.